Literature DB >> 11669332

Low-energy electron emitters for targeted radiotherapy of small tumours.

P Bernhardt1, E Forssell-Aronsson, L Jacobsson, G Skarnemark.   

Abstract

The possibility of using electron emitters to cure a cancer with metastatic spread depends on the energy of the emitted electrons. Electrons with high energy will give a high, absorbed dose to large tumours, but the absorbed dose to small tumours or single tumour cells will be low, because the range of the electrons is too long. The fraction of energy absorbed within the tumour decreases with increasing electron energy and decreasing tumour size. For tumours smaller than 1 g, the tumour-to-normal-tissue mean absorbed dose-rate ratio, TND, will be low, e.g. for 131I and 90Y, because of the high energy of the emitted electrons. For radiotherapy of small tumours, radionuclides emitting charged particles with short ranges (a few microm) are required. A mathematical model was constructed to evaluate the relation between TND and electron energy, photon-to-electron energy ratio, p/e, and tumour size. Criteria for the selection of suitable radionuclides for the treatment of small tumours were defined based on the results of the TND model. In addition, the possibility of producing such radionuclides and their physical and chemical properties were evaluated. Based on the mathematical model, the energy of the emitted electrons should be < or = 40 keV for small tumours (< 1000 cells), and the photon-to-electron energy ratio, p/e, should be < or = 2 to achieve a high TND. Using the selection criteria defined, five low-energy electron emitters were found to be suitable: 58Co, 103mRh, 119Sb, 161Ho, and 189mOs. All of these nuclides decay by internal transition or electron capture, which yields conversion and Auger electrons, and it should be possible to produce most of them in therapeutic amounts. The five low-energy electron-emitting radionuclides identified may be relevant in the radiation treatment of small tumours, especially if bound to internalizing radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669332     DOI: 10.1080/028418601750444141

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  17 in total

1.  Nuclear excitation functions of proton-induced reactions (Ep = 35 - 90 MeV) from Fe, Cu, and Al.

Authors:  Stephen A Graves; Paul A Ellison; Todd E Barnhart; Hector F Valdovinos; Eva R Birnbaum; Francois M Nortier; Robert J Nickles; Jonathan W Engle
Journal:  Nucl Instrum Methods Phys Res B       Date:  2016-09-28       Impact factor: 1.377

Review 2.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

3.  Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Authors:  H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2017-09-06       Impact factor: 1.513

4.  Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.

Authors:  Jenny Oddstig; Peter Bernhardt; Helena Lizana; Ola Nilsson; Håkan Ahlman; Lars Kölby; Eva Forssell-Aronsson
Journal:  Tumour Biol       Date:  2011-11-23

5.  Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Maria Leimer; Shuren Li; Fritz Andreae; Peter Angelberger; Robert Dudczak; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-21       Impact factor: 9.236

6.  In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Authors:  Flavio Forrer; Jianhua Chen; Melpomeni Fani; Pia Powell; Andreas Lohri; Jan Müller-Brand; Gerhard Moldenhauer; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

7.  Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Shuren Li; Bettina Ibi; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-21       Impact factor: 9.236

8.  First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.

Authors:  Richard P Baum; Aviral Singh; Harshad R Kulkarni; Peter Bernhardt; Tobias Rydén; Christiane Schuchardt; Nadezda Gracheva; Pascal V Grundler; Ulli Köster; Dirk Müller; Michael Pröhl; Jan Rijn Zeevaart; Roger Schibli; Nicholas P van der Meulen; Cristina Müller
Journal:  J Nucl Med       Date:  2021-02-05       Impact factor: 10.057

9.  Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119

Authors:  Parmissa Randhawa; Aeli P Olson; Shaohuang Chen; Kaley Lexi Gower-Fry; Cornelia Hoehr; Jonathan W Engle; Caterina F Ramogida; Valery Radchenko
Journal:  Curr Radiopharm       Date:  2021

10.  Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.

Authors:  Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.